Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.

Hydroxymethylacylfulvene (HMAF, MGI 114) is derived from the sesquiterpene illudin S by treatment with dilute sulfuric acid and excess paraformaldehyde. It is less cytotoxic than illudin S but exhibits much greater selectivity in toxicity to malignant cells compared to normal cells. HMAF is believed to undergo bioreductive activation in vivo. It is now being tested in human clinical phase II trials against solid tumors.

[1]  D. Troyer,et al.  Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). , 1997, Biochemical pharmacology.

[2]  M. Kelner,et al.  Synthesis of [3H]‐illudin S, [3H]‐acylfulvene, [3H] & [14C]‐hydroxymethylacylfulvene (MGI 114) , 1998 .

[3]  J. Ammirati,et al.  Poisonous mushrooms of the northern United States and Canada , 1985 .

[4]  J. Yu,et al.  Reaction of antitumor hydroxymethylacylfulvene (HMAF) with thiols , 1997 .

[5]  J. R. Hanson,et al.  Incorporation of [2-3H2]- and [4(R)-4-3H]-mevalonoid hydrogen atoms into the sesquiterpenoid illudin M , 1973 .

[6]  M. Kelner,et al.  Structure-activity relationships of illudins: analogs with improved therapeutic index. , 1992 .

[7]  J. Yu,et al.  Total synthesis of hydroxymethylacylfulvene, an antitumourderivative of illudin S , 1997 .

[8]  William Bauta,et al.  Design, synthesis, and antitumor activity of bicyclic and isomeric analogues of illudin M , 1996 .

[9]  Takeshi Matsumoto,et al.  An alternative synthesis of illudin M , 1970 .

[10]  T. Mcmorris,et al.  The Structures of the Basidiomycete Metabolites Illudin S and Illudin M , 1963 .

[11]  T. Mcmorris,et al.  The biogenesis of illudins S and M in clitocybe illudens , 1970 .

[12]  T. Mcmorris,et al.  FUNGAL METABOLITES. THE STRUCTURES OF THE NOVEL SESQUITERPENOIDS ILLUDIN-S AND -M. , 1965, Journal of the American Chemical Society.

[13]  A. Ichihara,et al.  Structure of lampterol (illudin S). , 1965, Tetrahedron.

[14]  M. Montoya,et al.  Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. , 1994, Biochemical pharmacology.

[15]  T. Mcmorris,et al.  Metabolites of Clitocybe illudens. IV. Illudalic acid, a sesquiterpenoid, and illudinine, a sesquiterpenoid alkaloid. , 1969, The Journal of organic chemistry.

[16]  T. Mcmorris,et al.  Fulvenes derived from illudin S , 1971 .

[17]  S. Kadota,et al.  Metabolism by rat liver cytosol of illudin S, a toxic substance of Lampteromyces japonicus. II. Characterization of illudin S-metabolizing enzyme. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Takeshi Matsumoto,et al.  Synthesis of illudin S , 1971 .

[19]  T. Anke,et al.  LEAIANAFULVENE, A SESQUITERPENOID FULVENE DERIVATIVE FROM CULTURES OF MYCENA LEAIANA , 1990 .

[20]  Y. Tezuka,et al.  Metabolism of illudin S, a toxic substance of Lampteromyces japonicus: urinary excretion of mercapturic acids in rat. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  A. Padwa,et al.  An Approach toward the Illudin Family of Sesquiterpenes Using the Tandem Cyclization−Cycloaddition Reaction of Rhodium Carbenoids , 1997 .

[22]  T. Mcmorris,et al.  On the mechanism of toxicity of illudins: the role of glutathione. , 1990, Chemical research in toxicology.

[23]  T. Mcmorris,et al.  An efficient synthesis of pterosin C and other pterosins , 1984 .

[24]  Y. Hu,et al.  Design and Synthesis of Antitumor Acylfulvenes. , 1997, The Journal of organic chemistry.

[25]  W. J. Robbins,et al.  Antibiotic substances from Basidiomycetes+. VII. Clitocybe illudens. , 1950, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Mcmorris,et al.  Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. , 1990, Journal of the National Cancer Institute.

[27]  R. Taetle,et al.  Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. , 1998, European journal of cancer.

[28]  K. Bair,et al.  TOTAL SYNTHESIS OF ()-ILLUDIN M , 1994 .

[29]  A. Arnone,et al.  Secondary mould metabolites. Part 31. Isolation and structure elucidation of illudins A and B, and illudalenol, new sesquiterpenoids from Clitocybe illudens , 1991 .

[30]  M. Kelner,et al.  Metabolism of antitumor acylfulvene by rat liver cytosol. , 1999, Biochemical pharmacology.

[31]  T. Mcmorris,et al.  (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. , 1996, Journal of natural products.

[32]  M. Uesugi,et al.  DNA damage by ptaquiloside, a potent bracken carcinogen: detection of selective strand breaks and identification of DNA cleavage products , 1994 .

[33]  K. Nakanishi,et al.  Illudin S (lampterol). , 1965, Tetrahedron.

[34]  M. Kelner,et al.  Structure and reactivity of illudins , 1989 .